ISX-9 Promotes KGF Secretion From MSCs to Alleviate ALI Through NGFR-ERK-TAU-<b>β</b>-Catenin Signaling Axis

The study investigates the potential of isoxazole-9 (ISX-9) to enhance the therapeutic effects of mesenchymal stem cells (MSCs) in treating acute lung injury (ALI) by promoting the secretion of keratinocyte growth factor (KGF). ISX-9 was found to increase KGF expression in MSCs by acting on the NGFR-ERK-TAU-β-catenin signaling axis. In an ALI model, the combination of ISX-9 and MSCs improved KGF expression in the lungs, reduced inflammation, and enhanced lung repair more effectively than MSCs alone. This suggests that ISX-9 can significantly boost the paracrine and anti-inflammatory functions of MSCs, offering a promising approach for ALI treatment.